BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd., a leading cellular and immune therapeutics company, today announced the pricing of its initial public offering of 6,250,000 ordinary shares at a public offering price of $8.00 per share for aggregate gross proceeds of $50.0 million. All of the shares in the offering are being offered by Gamida Cell. In addition, Gamida Cell granted the underwriters a 30-day option to purchase up to 937,500 additional ordinary shares at the initial offering price, less underwriting discounts and commissions. Gamida Cell’s ordinary shares are expected to begin trading on the Nasdaq Global Market on October 26, 2018, under the ticker symbol “GMDA.” The offering is expected to close on or about October 30, 2018, subject to customary closing conditions.
BMO Capital Markets and RBC Capital Markets are acting as joint book-running managers for this offering. Needham & Company and Oppenheimer & Co. are acting as co-lead managers for this offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 26, 2018. This offering will be made only by means of a prospectus. Copies of the final prospectus related to this offering may be obtained, when available, from: BMO Capital Markets, 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, Telephone: (800) 414-3627, Email: firstname.lastname@example.org; or RBC Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, Attention: Equity Syndicate Department, Telephone: (877) 822-4089, Email: email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Gamida Cell
Gamida Cell is a clinical stage biopharmaceutical company leveraging its proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The company is leveraging its nicotinamide-, or NAM-, based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies.
Forward Looking Statements
This press release contains forward-looking statements, including with respect to the expected closing of Gamida Cell’s initial public offering. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including that the conditions to the closing of the initial public offering are not satisfied. Gamida Cell undertakes no obligation to update any such forward-looking statements after the date hereof, except as required by law.